NeoGenomics (NASDAQ:NEO - Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $20.00 to $18.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the medical research company's stock. The Goldman Sachs Group's target price indicates a potential upside of 18.58% from the stock's previous close.
A number of other brokerages have also recently weighed in on NEO. Jefferies Financial Group started coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price target for the company. Benchmark downgraded NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Needham & Company LLC restated a "buy" rating and set a $19.00 price target on shares of NeoGenomics in a research note on Friday, January 10th. Finally, Bank of America boosted their price objective on NeoGenomics from $18.00 to $19.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, NeoGenomics presently has a consensus rating of "Moderate Buy" and an average price target of $20.20.
View Our Latest Analysis on NEO
NeoGenomics Stock Up 0.9 %
Shares of NeoGenomics stock traded up $0.14 on Tuesday, reaching $15.18. 537,493 shares of the company were exchanged, compared to its average volume of 1,258,853. The stock's 50 day moving average price is $16.53 and its 200-day moving average price is $15.72. The company has a market cap of $1.95 billion, a P/E ratio of -24.88 and a beta of 1.24. NeoGenomics has a 1-year low of $12.13 and a 1-year high of $19.11. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91.
NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.04. The business had revenue of $167.80 million for the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The company's revenue was up 10.5% on a year-over-year basis. During the same period last year, the business earned ($0.06) EPS. As a group, equities analysts forecast that NeoGenomics will post -0.16 EPS for the current year.
Insider Activity at NeoGenomics
In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the company's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company's stock, valued at $570,301.44. This represents a 12.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by insiders.
Institutional Investors Weigh In On NeoGenomics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Loomis Sayles & Co. L P purchased a new position in NeoGenomics during the 3rd quarter valued at about $17,807,000. Segall Bryant & Hamill LLC grew its position in shares of NeoGenomics by 67.0% in the third quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company's stock valued at $27,928,000 after purchasing an additional 759,524 shares during the last quarter. Bellevue Group AG increased its stake in shares of NeoGenomics by 34.2% during the 3rd quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company's stock worth $23,786,000 after purchasing an additional 410,516 shares in the last quarter. Jennison Associates LLC increased its stake in shares of NeoGenomics by 18.7% during the 4th quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock worth $24,963,000 after purchasing an additional 238,288 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of NeoGenomics by 152.6% during the 2nd quarter. Sei Investments Co. now owns 263,761 shares of the medical research company's stock worth $3,658,000 after purchasing an additional 159,350 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
